Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
sell

Regeneron Pharmaceuticals Inc. sell Bank of America Co.

Regeneron Pharmaceuticals Inc.
Start price
€756.00
29.03.23 / 50%
Target price
€599.43
29.03.24
Performance (%)
19.37%
End price
€902.40
30.03.24
Summary
This prediction ended on 30.03.24 with a price of €902.40. The SELL prediction by Bank_of_America_Co_ finished with a performance of 19.37%. Bank_of_America_Co_ has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Sell. Bank_of_America_Co_ has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 6.613% 6.613% -7.915%
iShares Core DAX® 0.060% 1.215% 18.128%
iShares Nasdaq 100 -3.065% -0.519% 2.080%
iShares Nikkei 225® -2.094% -3.066% 11.655%
iShares S&P 500 -1.657% -0.069% 1.103%

Comments by Bank_of_America_Co_ for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Sell
Perf. (%) 19.37%
Target price 599.430
Change
Ends at 29.03.24

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at Bank of America Co. from $605.00 to $650.00. They now have an "underperform" rating on the stock.
Ratings data for REGN provided by MarketBeat

Bank of America Co. 
0
Report Share
29.03.23
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Sell
Perf. (%) 19.37%
Target price 599.430
Change
Ends at 29.03.24

Die von Bank_of_America_Co_ gewählte maximale Laufzeit wurde überschritten

Bank of America Co. 
0
Report Share
30.03.24

Current prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.

sell
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€480.80
17.04.25
€481.36
17.04.26
33.20%
18:16

Bank of America Co. 
17.04.25 50%

Stopped prediction by Bank_of_America_Co_ for Regeneron Pharmaceuticals Inc.

sell
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€851.20
12.04.24
€676.58
12.04.25
-41.86%
13.04.25

Bank of America Co. 
12.04.24 50%